The development of vascular endothelial growth factor receptor (VEGFR)-targeted therapies and immune checkpoint inhibitors (ICIs) has revolutionized the management of metastatic RCC and prompted investigation in earlier disease settings [5]. The gene discussed is KDR; the disease is renal cell carcinoma.